An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study
- PMID: 36011034
- PMCID: PMC9406336
- DOI: 10.3390/cancers14164041
An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study
Abstract
Background: Artificial intelligence (AI) has contributed substantially in recent years to the resolution of different biomedical problems, including cancer. However, AI tools with significant and widespread impact in oncology remain scarce. The goal of this study is to present an AI-based solution tool for cancer patients data analysis that assists clinicians in identifying the clinical factors associated with poor prognosis, relapse and survival, and to develop a prognostic model that stratifies patients by risk.
Materials and methods: We used clinical data from 5275 patients diagnosed with non-small cell lung cancer, breast cancer, and non-Hodgkin lymphoma at Hospital Universitario Puerta de Hierro-Majadahonda. Accessible clinical parameters measured with a wearable device and quality of life questionnaires data were also collected.
Results: Using an AI-tool, data from 5275 cancer patients were analyzed, integrating clinical data, questionnaires data, and data collected from wearable devices. Descriptive analyses were performed in order to explore the patients' characteristics, survival probabilities were calculated, and a prognostic model identified low and high-risk profile patients.
Conclusion: Overall, the reconstruction of the population's risk profile for the cancer-specific predictive model was achieved and proved useful in clinical practice using artificial intelligence. It has potential application in clinical settings to improve risk stratification, early detection, and surveillance management of cancer patients.
Keywords: artificial intelligence; cancer patients; data integration; decision support system; patient stratification; precision oncology.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Potential Prognostic Immune Biomarkers of Overall Survival in Ovarian Cancer Through Comprehensive Bioinformatics Analysis: A Novel Artificial Intelligence Survival Prediction System.Front Med (Lausanne). 2021 May 24;8:587496. doi: 10.3389/fmed.2021.587496. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34109184 Free PMC article.
-
Application of Artificial Intelligence in Pharmaceutical and Biomedical Studies.Curr Pharm Des. 2020;26(29):3569-3578. doi: 10.2174/1381612826666200515131245. Curr Pharm Des. 2020. PMID: 32410553 Review.
-
Tumor burden of lung metastases at initial staging in breast cancer patients detected by artificial intelligence as a prognostic tool for precision medicine.Heliyon. 2022 Feb 15;8(2):e08962. doi: 10.1016/j.heliyon.2022.e08962. eCollection 2022 Feb. Heliyon. 2022. PMID: 35243082 Free PMC article.
-
Applying Artificial Intelligence to Gynecologic Oncology: A Review.Obstet Gynecol Surv. 2021 May;76(5):292-301. doi: 10.1097/OGX.0000000000000902. Obstet Gynecol Surv. 2021. PMID: 34032861 Review.
-
An overview of artificial intelligence in oncology.Future Sci OA. 2022 Feb 10;8(4):FSO787. doi: 10.2144/fsoa-2021-0074. eCollection 2022 Apr. Future Sci OA. 2022. PMID: 35369274 Free PMC article. Review.
Cited by
-
Patient Consent and The Right to Notice and Explanation of AI Systems Used in Health Care.Am J Bioeth. 2025 Mar;25(3):102-114. doi: 10.1080/15265161.2024.2399828. Epub 2024 Sep 17. Am J Bioeth. 2025. PMID: 39288291 Free PMC article.
-
Integrating Artificial Intelligence-Driven Wearable Technology in Oncology Decision-Making: A Narrative Review.Oncology. 2025;103(1):69-82. doi: 10.1159/000540494. Epub 2024 Jul 25. Oncology. 2025. PMID: 39072365 Free PMC article. Review.
-
Artificial intelligence in neuro-oncology: methodological bases, practical applications and ethical and regulatory issues.Clin Transl Oncol. 2025 May 22. doi: 10.1007/s12094-025-03948-4. Online ahead of print. Clin Transl Oncol. 2025. PMID: 40402414 Review.
-
Menopausal Status Contributes to Overall Survival in Endometrial Cancer Patients.Cancers (Basel). 2023 Jan 10;15(2):451. doi: 10.3390/cancers15020451. Cancers (Basel). 2023. PMID: 36672399 Free PMC article.
-
Importance of Health Economics and Outcomes Research in the Product Lifecycle.Pharmaceut Med. 2025 May;39(3):157-170. doi: 10.1007/s40290-025-00564-z. Epub 2025 Apr 14. Pharmaceut Med. 2025. PMID: 40227495 Review.
References
-
- Hamamoto R., Suvarna K., Yamada M., Kobayashi K., Shinkai N., Miyake M., Takahashi M., Jinnai S., Shimoyama R., Sakai A., et al. Application of artificial intelligence technology in oncology: Towards the establishment of precision medicine. Cancers. 2020;12:3532. doi: 10.3390/cancers12123532. - DOI - PMC - PubMed
-
- Lu C., Bera K., Wang X., Prasanna P., Xu J., Janowczyk A., Beig N., Yang M., Fu P., Lewis J., et al. A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: A multicentre, retrospective study. Lancet Digit. Health. 2020;2:e594–e606. doi: 10.1016/S2589-7500(20)30225-9. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources